Letrostar

Letrozole, the active ingredient in Letrostar, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the endocrine treatment of postmenopausal estrogen receptor‑positive breast cancer, reducing estrogen production that can stimulate tumor growth and is commonly prescribed as part of a comprehensive oncology regimen.

GNH USA supplies Letrostar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across multiple regions.

Letrozole is an aromatase inhibitor used in the management of estrogen‑driven breast cancer. - Postmenopausal estrogen receptor‑positive breast cancer: Reduces tumor progression by lowering systemic estrogen levels. - Metastatic hormone‑receptor‑positive breast cancer: Provides disease control when combined with other endocrine agents. - Adjuvant therapy for early‑stage ER‑positive breast cancer: Decreases risk of recurrence after surgery.

Letrozole may cause a range of adverse reactions, varying from mild to serious. Common Side Effects: - Hot flashes: Sudden warmth and sweating. - Joint and muscle pain: Arthralgia and myalgia. - Nausea: Mild gastrointestinal upset. Serious or Rare Side Effects: - Osteoporosis: Decreased bone density with fracture risk. - Elevated liver enzymes: Possible hepatic injury. - Severe allergic reaction: Rash, swelling, or anaphylaxis.

When prescribing Letrozole, clinicians should consider several safety precautions to minimize risk. - Assess bone health: Baseline DEXA scan recommended due to risk of osteoporosis. - Monitor liver function: Periodic tests for hepatic enzyme elevation. - Evaluate cardiovascular risk: Caution in patients with history of thromboembolic disease. - Avoid use in pregnancy: Contraindicated in women of childbearing potential unless effective contraception is used. - Review drug interactions: Check concomitant medications that affect CYP3A4. - Store at ambient temperature: Keep below 25 °C in original packaging, protect from moisture.

Letrozole can interact with other medicines, altering its effectiveness or safety profile. Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): May reduce letrozole plasma levels. - Antifungal azoles (e.g., ketoconazole): Can increase exposure, raising toxicity risk. Moderate Interactions (Monitor Closely): - Hormone replacement therapy: May diminish letrozole’s estrogen‑lowering effect. - Warfarin: Potential alteration of anticoagulant control; monitor INR. - Selective serotonin reuptake inhibitors: May increase risk of bone loss; observe bone health.